Advancing precision immunotherapy in advanced pancreatic cancer: a systematic review and meta-analysis of first-line ICI-based combinations
In brief
First-line immunotherapy combos achieve 38% response rate in advanced pancreatic cancer
In a meta-analysis of eight trials (379 patients), ICI-based combination regimens produced an overall response rate of 38%, roughly twice the response seen with checkpoint inhibitor monotherapy, and a median progression-free survival of about 6 months. Survival trends favored the combos but did not reach statistical significance, and higher-grade toxicities were more common yet manageable; larger randomized trials are required to confirm a survival benefit.
- Journal
- Frontiers in immunology (Q1)
- Published
- 10 July 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Xiaoqi Qi, Haoran Yang, Li Zhang, Peishi Yu, Can Cheng
- PMID
- 42500667
- DOI
- 10.3389/fimmu.2026.1855859
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (top studies of the week, 27 July 2026): Systematic review of ICI‑based combos in advanced pancreatic cancer
- Picked for Pharmacology (medical) (paper of the day, 26 July 2026).
- Picked for Endocrinology, Diabetes and Metabolism (top studies of the week, 26 July 2026).
- Picked for Genetics (clinical) (paper of the day, 26 July 2026).
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (top studies of the week, 26 July 2026): Systematic review/meta‑analysis of first‑line ICI‑based combos in PDAC
- Picked for Epidemiology (top studies of the week, 26 July 2026): Ranked by evidence level and journal quartile
Abstract
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. Immune checkpoint inhibitor (ICI) monotherapy has shown limited efficacy in PDAC, whereas the potential clinical value of first-line ICI-based combination regimens remains unclear. Through a systematic review and meta-analysis, this study aimed to evaluate the efficacy and safety of first-line ICI-based combination regimens in advanced PDAC. METHODS: PubMed, Embase, The Cochrane Library, Scopus, Web of Science, CNKI, Wanfang Data, VIP, and CBM were searched up to April 4, 2026, to identify clinical studies evaluating first-line ICI-based combination therapy for advanced PDAC. Study screening and data extraction were performed in accordance with PRISMA guidelines. RESULTS: Eight clinical trials involving 379 patients were included. In RCT-only analyses, ICI-based combination regimens showed favorable but statistically non-definitive trends for OS (HR = 0.83, 95% CI: 0.65-1.06) and PFS (HR = 0.75, 95% CI: 0.53-1.05), while ORR was improved (OR = 2.19, 95% CI: 1.32-3.64). Single-arm pooled analysis showed a median PFS of 6.2 months and an ORR of 38.0%. In terms of safety, combination therapy increased the risk of specific Grade 3 or higher adverse events, but the overall incidence was clinically manageable. CONCLUSION: First-line ICI-based combination regimens showed encouraging antitumor activity in advanced PDAC, particularly for radiological response. However, definitive survival benefits were not established in RCT-only analyses, and further large-scale randomized trials are needed. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261440306, identifier CRD420261440306.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.